WO2002053100A3 - Pharmaceutical dosage form for oral administration of low molecular weight heparin - Google Patents

Pharmaceutical dosage form for oral administration of low molecular weight heparin Download PDF

Info

Publication number
WO2002053100A3
WO2002053100A3 PCT/US2001/050752 US0150752W WO02053100A3 WO 2002053100 A3 WO2002053100 A3 WO 2002053100A3 US 0150752 W US0150752 W US 0150752W WO 02053100 A3 WO02053100 A3 WO 02053100A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecular weight
low molecular
oral administration
dosage form
weight heparin
Prior art date
Application number
PCT/US2001/050752
Other languages
French (fr)
Other versions
WO2002053100A2 (en
Inventor
Feng-Jing Chen
Mahesh V Patel
David T Fikstad
Original Assignee
Lipocine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipocine Inc filed Critical Lipocine Inc
Priority to AU2002243387A priority Critical patent/AU2002243387A1/en
Publication of WO2002053100A2 publication Critical patent/WO2002053100A2/en
Publication of WO2002053100A3 publication Critical patent/WO2002053100A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug, e.g., a polysaccharide drug such as a low molecular weight heparin, are provided. The dosage form comprises a composition of: (a) a therapeutically effective amount of low molecular weight heparin; (b) a bile salt or bile acid; (c) at least one surfactant selected form hydrophilic surfactants, lipophilic surfactants, and mixtures thereof; and a means for delaying release of the composition from the dosage form following oral administration. Osmotic drug delivery systems for oral administration of a hydrophilic drug are also provided, wherein an osmotically activated device houses the drug, a bile salt or bile acid, and at least one surfactant selected form the group consisting of hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. Methods for administering hydrophilic drugs, particularly polysaccharide drugs such as low molecular weight heparin, are also provided.
PCT/US2001/050752 2000-12-29 2001-12-28 Pharmaceutical dosage form for oral administration of low molecular weight heparin WO2002053100A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002243387A AU2002243387A1 (en) 2000-12-29 2001-12-28 Pharmaceutical dosage form for oral administration of low molecular weight heparin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/751,968 US6458383B2 (en) 1999-08-17 2000-12-29 Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US09/751,968 2000-12-29

Publications (2)

Publication Number Publication Date
WO2002053100A2 WO2002053100A2 (en) 2002-07-11
WO2002053100A3 true WO2002053100A3 (en) 2003-03-27

Family

ID=25024277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050752 WO2002053100A2 (en) 2000-12-29 2001-12-28 Pharmaceutical dosage form for oral administration of low molecular weight heparin

Country Status (3)

Country Link
US (1) US6458383B2 (en)
AU (1) AU2002243387A1 (en)
WO (1) WO2002053100A2 (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (en) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group New vaccine formulation
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
AR028023A1 (en) * 2000-04-19 2003-04-23 Borody Thomas J A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF MEDICINES
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
US8366787B2 (en) * 2000-08-04 2013-02-05 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
WO2002064148A2 (en) * 2001-02-16 2002-08-22 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US7846475B2 (en) * 2001-07-05 2010-12-07 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US8025896B2 (en) 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
AU2002354911B2 (en) 2001-07-16 2007-08-30 Depuy Products, Inc. Meniscus regeneration device and method
AU2002322567B2 (en) 2001-07-16 2007-09-06 Depuy Products, Inc. Devices form naturally occurring biologically derived
US7819918B2 (en) * 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
WO2003007787A2 (en) * 2001-07-16 2003-01-30 Depuy Products, Inc. Cartilage repair and regeneration device and method
EP1416874A4 (en) 2001-07-16 2007-04-18 Depuy Products Inc Hybrid biologic/synthetic porous extracellular matrix scaffolds
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
US6632449B2 (en) * 2001-11-20 2003-10-14 The Procter & Gamble Co. Compositions and kits comprising a defined boron compound and methods of their preparation
US9308220B2 (en) * 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
IL162294A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents
KR20040066177A (en) * 2001-12-19 2004-07-23 알자 코포레이션 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
KR100937113B1 (en) * 2002-01-16 2010-01-18 아스텔라스세이야쿠 가부시키가이샤 Medicinal compositions for improving oral absorption
BR0307913A (en) * 2002-02-25 2005-01-11 Lyfjathroun Hf Use of a composition, pharmaceutical composition for nasal administration, and methods to elicit a therapeutic, prophylactic and / or diagnostic effect in a mammal, to obtain a rapid onset of a therapeutic, prophylactic and / or diagnostic effect of an active substance in a mammal and to improve the bioavailability of a therapeutic, prophylactic and / or diagnostic effect of an active substance in a mammal
KR100439069B1 (en) * 2002-04-03 2004-07-05 노일근 Ultra-fine needle crystaline Ursodeoxycholic acid and process for preparation thereof
WO2003088980A1 (en) * 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
US20040091538A1 (en) * 2002-10-31 2004-05-13 Crystal Pollock-Dove Dosage form providing ascending release of liquid formulation
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
DE10307728B4 (en) * 2003-02-24 2005-09-22 Clariant Gmbh Corrosion and gas hydrate inhibitors with improved water solubility and increased biodegradability and such compounds
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
ES2496102T3 (en) * 2003-03-28 2014-09-18 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
CA2520886A1 (en) * 2003-04-02 2004-11-04 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
MXPA06003450A (en) 2003-09-26 2006-08-31 Johnson & Johnson Drug coating providing high drug loading and methods for providing the same.
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
AU2004285553B2 (en) * 2003-10-31 2009-12-10 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
BRPI0506764A (en) * 2004-01-09 2007-05-22 Wyeth Corp microemulsions for pharmaceutical compositions
AR043110A1 (en) * 2004-02-04 2005-07-20 Syntex Sa LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE
US20050214230A1 (en) * 2004-03-23 2005-09-29 J. B. Chemicals & Pharmaceuticals Ltd. Novel stomatological gel
WO2005089714A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion stabilizer
KR20070008720A (en) * 2004-05-06 2007-01-17 에미스페어 테크놀로지스, 인코포레이티드 Solid dosage form of wetted heparin
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006035418A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
EP2985026B1 (en) 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
EP1926474A1 (en) * 2005-07-21 2008-06-04 Mediplex Corp. Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
US8865197B2 (en) * 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
ITMI20052461A1 (en) * 2005-12-22 2007-06-23 Univ Degli Studi Milano MICROPARTELAR SYSTEMS FOR ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES
CA2655682A1 (en) 2006-08-03 2008-02-07 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
WO2008062475A2 (en) * 2006-10-26 2008-05-29 Cadila Healthcare Limited Pharmaceutical compositions of ursodiol
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
EP2066309B1 (en) 2007-04-04 2012-08-29 Sigmoid Pharma Limited An oral pharmaceutical composition
EP2586428B1 (en) * 2007-04-26 2023-11-08 Sublimity Therapeutics Limited Manufacture of multiple minicapsules
JP2010526053A (en) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド Nimodipine pharmaceutical composition
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009066146A2 (en) * 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
US10251839B2 (en) * 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
SI2432455T1 (en) 2009-05-18 2015-04-30 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2011038120A1 (en) * 2009-09-25 2011-03-31 Pharmasol Corporation Surface coatings for skin
CN102711463B (en) 2009-12-03 2015-05-13 Opko健康公司 Hypersulfated disaccharide formulations
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2512448B1 (en) 2009-12-18 2016-07-06 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
EP2682111A1 (en) 2009-12-31 2014-01-08 Differential Drug Development Associates LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
RS55372B1 (en) 2011-04-29 2017-03-31 Moberg Pharma Ab Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
TW201311296A (en) * 2011-07-01 2013-03-16 Gelita Ag Novel gelatin capsule compositions and methods of making
US20140046052A1 (en) * 2011-09-21 2014-02-13 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
CN103182033B (en) * 2011-12-28 2017-07-04 安徽中医药大学 One kind treats ishemic stroke Chinese medicine compound prescription preparation of active ingredient and preparation method thereof
JP6174601B2 (en) * 2012-01-03 2017-08-02 オラムド エルティーディー． Methods and compositions for treating diabetes
EP2834635A4 (en) * 2012-04-03 2015-09-02 Smiths Medical Asd Inc Heparin-bulking agent compositions and methods thereof
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN103705608A (en) * 2012-10-07 2014-04-09 上海中医药大学附属曙光医院 Medicine preparation used for treating chronic cardiac failure and preparing method thereof
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
WO2014143127A1 (en) 2013-03-15 2014-09-18 Differential Drug Development Associates Llc Emulsion formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN103800443A (en) * 2014-01-22 2014-05-21 北京大学 Anti-gout traditional Chinese medicinal formulation and preparation method thereof
EP2923710A1 (en) * 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
KR101528476B1 (en) * 2014-10-07 2015-06-12 네오지에이지주식회사 Enhanced drug delivery formulation for mesoglycan
CA2966801A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
TW201739455A (en) 2016-04-19 2017-11-16 菲林公司 Oral pharmaceutical compositions of nicotinamide
CA3021071A1 (en) 2016-04-19 2017-10-26 Ferring B.V. Oral pharmaceutical compositions of mesalazine
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3634507A4 (en) * 2017-06-07 2021-03-24 EGY-Nano Pharma, LP Oral prolonged drug delivery platforms
CN107375406A (en) * 2017-07-26 2017-11-24 广西中医药大学 It is a kind of that there is anti-inflammatory, the imperial sharp leaf extract and its preparation of antitussive action
US20220380761A1 (en) 2021-04-22 2022-12-01 Civi Biopharma, Inc. Oral delivery of oligonucleotides
US11337987B1 (en) 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
CN115381851B (en) * 2022-07-06 2023-12-19 重庆市妇幼保健院(重庆市妇产科医院、重庆市遗传与生殖研究所) Self-assembled nano anticoagulant and thrombolytic medicine, preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510561A (en) * 1965-05-20 1970-05-05 Canada Packers Ltd Sulfone-enhanced heparin absorption through mucous membranes
US4579730A (en) * 1983-05-23 1986-04-01 Hadassah Medical Organization Pharmaceutical compositions containing insulin
US4727109A (en) * 1985-01-04 1988-02-23 R. P. Scherer Corporation Pharmaceutical preparation with an active substance of low solubility in water and gastric juices

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (en) 1976-10-23 1978-07-21 Choay Sa PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS
JPS53107408A (en) 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
SE445174B (en) 1978-03-07 1986-06-09 Sandoz Ag PHARMACEUTICAL COMPOSITION CONTAINING A CYCLOSPORIN AND A HEALING SUBSTANCE
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
US4654327A (en) 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
DE3237814A1 (en) 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. WATER-FREE EMULSIONS AND USE THEREOF
SE8206744D0 (en) 1982-11-26 1982-11-26 Fluidcarbon International Ab PREPARATION FOR CONTROLLED RELEASE OF SUBSTANCES
DE3331009A1 (en) 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
DE3406497A1 (en) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION
US4713246A (en) 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US4572915A (en) 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4703042A (en) 1984-05-21 1987-10-27 Bodor Nicholas S Orally active heparin salts containing multivalent cationic units
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
SE457693B (en) 1986-07-01 1989-01-23 Drilletten Ab COMPOSITION WITH REGULATED RELEASE WAS A BIOLOGICAL MATERIAL LOST OR DISPERSED IN AN L2 PHASE
KR950014440B1 (en) * 1986-08-11 1995-11-28 이노바타 바이오메드 리미티드 Phamacentical formulation comprising microcapsules
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5244925A (en) 1987-12-18 1993-09-14 Kabi Pharmacia Aktiebolag Emulsion for parenteral administration
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
DE3919982A1 (en) 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh ORAL LIPID MEDICINE FORM
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
WO1992003121A1 (en) 1990-08-13 1992-03-05 Yesair David W Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IT1245761B (en) * 1991-01-30 1994-10-14 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
JPH06507172A (en) 1991-04-19 1994-08-11 アフィニティー　バイオテック，インコーポレイテッド Convertible microemulsion formulation
US5688761A (en) 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
AU661080B2 (en) 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
SE9200951D0 (en) 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
IT1255449B (en) 1992-06-30 1995-10-31 Fabio Berlati USE OF NOR- AND HOMO-DERIVATIVES OF BILE ACIDS AS DRUGS ABSORPTION PROMOTERS.
GB9300875D0 (en) 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
SE9302135D0 (en) 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
ES2068762B1 (en) 1993-07-21 1995-12-01 Lipotec Sa A NEW PHARMACEUTICAL PREPARATION TO IMPROVE THE BIOAVAILABILITY OF DRUGS OF DIFFICULT ABSORPTION AND PROCEDURE FOR THEIR OBTAINING.
DE69434626D1 (en) * 1993-11-17 2006-04-20 Athena Neurosciences Inc TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS
DE4340781C3 (en) 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
SE518578C2 (en) 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
SE518619C2 (en) 1994-12-09 2002-10-29 Gs Dev Ab Controlled release composition containing monocaproin
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
JP2740153B2 (en) 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー Mixed micelle
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510561A (en) * 1965-05-20 1970-05-05 Canada Packers Ltd Sulfone-enhanced heparin absorption through mucous membranes
US4579730A (en) * 1983-05-23 1986-04-01 Hadassah Medical Organization Pharmaceutical compositions containing insulin
US4727109A (en) * 1985-01-04 1988-02-23 R. P. Scherer Corporation Pharmaceutical preparation with an active substance of low solubility in water and gastric juices

Also Published As

Publication number Publication date
US6458383B2 (en) 2002-10-01
US20010024658A1 (en) 2001-09-27
AU2002243387A1 (en) 2002-07-16
WO2002053100A2 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
WO2002053100A3 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
WO2001089479A3 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
CO5560580A2 (en) FORMULATIONS OF SUCRALOSE TO DISPENSE FLAVORABLE FLAVORS
WO2002007712A3 (en) Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
WO2004002447A3 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
DK1183014T3 (en) Flavored controlled release oral pharmaceutical compositions
WO1999053910A8 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
WO2005048952A3 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
CA2337046A1 (en) Sustained release pharmaceutical preparation
BR9607234A (en) Mucoadhesive granules use the same process for their preparation, pharmaceutical composition and use
NZ501950A (en) Medicinal compositions for application to mucosa
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2002039993A3 (en) Pharmaceutival preparations comprising corticosteroids and antiinfective agents
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
MY144021A (en) Pharmaceutical delivery system
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2002085304A3 (en) Proliposomal drug delivery system
WO2005020959A3 (en) Novel drug compositions and dosage forms of topiramate
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
WO2003041656A3 (en) Soluble drug extended release system
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
DE60316714D1 (en) PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP